Investors
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.
Investors
Investors
Our business
Financial Resources
Shareholder Resources
American Depository Share payment history
AGM Notice of Meeting
AGM Notice of Meeting Archive
AGM Poll Results Archive
American Depository Shares
Dividend payment history
DRIP payment history
Quarterly Reporting Archive
Regulations And Compliance
Section 172 Statement
Share Price Chart
Stock Exchange announcements
Email Alerts
Q1 2024 Results Webcast
We released our first quarter 2024 results on Wednesday 1 May 2024.
Webcast
The webcast is available to play back at the link below.
Financial calendar
Annual General Meeting
News and Announcements
Investors
Capital Allocations Framework
1. Invest
- Innovation to drive organic growth
- Sustainability targets and further embed our ESG agenda
2. Acquire
- New technologies and expand in high growth segments with strong strategic fit and meet our financial criteria
3. Maintain
- Optimal balance sheet position:
- Investment grade credit ratings
- Leverage ratio of around 2x
- Dividend:
- 2024: Consistent with recent years at $37.5c for full year with an interim payment of $14.4c
- 2025 onwards: Progressive with a payout ratio of around 35% - 40%
- Interim payment of 40% of prior full year dividend
4. Return
- Surplus capital to shareholders through a regular annual buyback.
- Share buyback subject to balance sheet
